drugset
drugset / Trial / NCT06988956

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

NCT06988956 ↗

Phase 2 Recruiting 95 enrolled The First Affiliated Hospital with Nanjing Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.

Timeline

Start
2024-03-31
Primary completion
2027-04-01
Completion
2027-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg Intravenous
Background Tegafur Unknown 40 mg Oral
Background Tegafur Unknown 50 mg Oral
Background Tegafur Unknown 60 mg Oral
Background Tegafur Unknown 60 mg/m2 Oral

Indications

esophageal squamous cell carcinoma